Utility of PET to Appropriately Select Patients for PSMA-Targeted Theranostics
Sign Up to like & getrecommendations! Published in 2022 at "Clinical Nuclear Medicine"
DOI: 10.1097/rlu.0000000000004196
Abstract: Abstract The majority of aggressive prostate cancers overexpress the transmembrane protein prostate-specific membrane antigen (PSMA). PSMA is, therefore, an attractive target for drug development. Over the last decade, numerous PSMA-targeted radiopharmaceuticals for imaging and therapy… read more here.
Keywords: patients psma; prostate; pet; psma targeted ... See more keywords